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Cardiovascular surgery as a surgical discipline is less than
a century old. Its birth coincided with a change in the
prevailing philosophy of surgical practice from removal to
repair. The earliest experiments with venous autografts
were those of Gluck, Exner and Hopfner. However, these
vein grafts all failed. Carrel and Guthrie successfully pio-
neered experimental autogenous vein bypass grafting.1 In
1906, Goyanes inserted the first autogenous vein graft into
a human, using a popliteal vein as an interposition graft to
bridge an arterial defect, following excision of a syphilitic
popliteal aneurysm2 and in the same year, Lexer interposed
a segment of great saphenous vein to bridge an arterial
defect following excision of a posttraumatic axillary artery
aneurysm.3 However, this patient died shortly thereafterlished in Eur J Vasc Endovasc
gen, Duke University Medical
USA.
lsevier Ltd on behalf of Europeanand at autopsy, a clamp induced, non-occluding thrombus
on the inner wall of the axillary artery was observed. This
was the first description of the consequences of intimal
injury. In the following two decades, vascular procedures
did not gain popular acceptance because of inaccurate
preoperative diagnoses and frequent perioperative distal
thrombotic events. The development of contrast angiog-
raphy and the introduction of heparin resolved these major
impediments to such an extent that the risk to benefit ratio
for bypass procedures became acceptable. Kunlin in 1949
described the modern popliteal bypass4 and Holden in 1950
reported the use of the saphenous vein to bypass an
occluded superficial femoral artery.5 By 1962, the devel-
opment of selective coronary angiography allowed Sabiston
to perform the first right coronary artery bypass proce-
dure.6 The art of coronary artery bypass grafting was
further developed and refined by Garret and Favaloro.7,8
Although refinements in techniques and suture materials
continue to occur, the guiding principles of the early
surgeons are still applicable. Further advance in peripheral
arterial vein bypassing came with the introduction of theSociety for Vascular Surgery.
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technique was the belief that explantation of the vein
produced considerable endothelial and mural injury that
was contributing to the high failure rates. Although Rob per-
formed the first modern successful in-situ bypass in 1959,9 it
was Hall who pioneered the principle, introduced technical
modifications and developed a valvulotome.10 The in-situ
technique did not enter into widespread use until the reports
of Leather andKarmody appeared, detailing impressive short-
and long-term patency results.11,12 The debate on the
advantages of the in-situ technique compared to the reversed
vein grafts is ongoing and at present it appears that there are
equivalent patency rates for both types of grafts in all
positions.
Clinical graft patency of autogenous saphenous vein
grafts in the arterial circulation can be divided into three
temporal categories: early (0 to 30 days), short-term (30
days to 2 years) or long-term (greater than 2 years).
Generically the causes of these failures may be classified as
either intrinsic or extrinsic (Table 1). Early failures are
ascribed to either technical failures occurring at the anas-
tomoses, the position of the graft, kinking of the graft or
initial poor distal runoff and account for less than 5% of all
vein graft occlusions. The number of occlusions due to
technical difficulties or inappropriate graft placement into
poor inflow/runoff tracts is unlikely to diminish further
given the present level of vascular diagnosis and surgical
expertise. Short-term failures are due predominantly to the
development of intimal hyperplasia within the graft.
Generally, short-term patency rates range from 80-90% with
a subsequent annual failure rate of 2 to 5%. Up to 30% of
vein grafts will require intervention within two years due to
the development of haemodynamically significant intimal
hyperplastic lesions (graft stenoses).13 The etiology of long-
term failure is still unclear but a combination of progression
of the host’s underlying disease, increased graft intimal
hyperplasia and the development of atherosclerosis-like
lesions within the vein graft appear to be the principal
causes.
The concept of the “failing graft”, is one of a patent
graft, whose patency is threatened by a haemodynami-
cally significant lesion in the inflow/outflow tracts or
within the body of the graft. Salvage of “failing” and
failed bypass grafts remains an important clinical and
technical challenge. As many as 80% of patients who
present with recurrent limb ischaemia have an occluded
graft and the patency of these occluded vein grafts after
revision is often extremely poor.14,15 This bleak outcome
with occlusion has led to the evolution of graftTable 1 Mechanisms of vein graft failure.
Intrinsic
Poor vein quality
Missed valve/branch (in- situ)
Branch ligature placement
Intimal flaps
Intimal hyperplasia (anastomotic or intra-graft)
Accelerated atherosclerosis
Aneurysmal degenerationsurveillance programs to detect “failing” grafts and has
spurred research on means to control the development of
intimal hyperplasia.
The increasing use of autogenous vein grafting proce-
dures and the heightened awareness of its pathological
sequelae has stimulated interest in venous biology and the
biological consequences upon the vein of being placed in
the arterial system. Studies of human veins harvested for
bypass procedures have revealed that many have
abnormal histologic and physiologic attributes.16e20
Furthermore, the quality of the saphenous vein can have
significant clinical consequences.21,22 Vein grafts in the
arterial circulation, must be considered as a viable,
constantly adapting and evolving conduit. This review
examines the physiology, pharmacology and pathology of
veins and vein grafts in the preoperative, perioperative
and postoperative periods. Better definition and under-
standing of the biological events during these periods
should allow an accurate definition of the pathophysiology
of vein graft failure and the development of new inter-
ventional therapies.Preoperative Period
The wall of a vein is traditionally divided into three
anatomic layers: the intima, the media and the adventitia.
The intima is composed of a thin layer of endothelial cells
beneath which is a fenestrated basement membrane,
a subendothelial matrix of glycoproteins and connective
tissue elements, and occasional intimal cells. In the
media, the smooth muscle cells are arranged in an inner
longitudinal and an outer circumferential pattern with
collagen and elastic fibrils interlaced. The elastic fibrils
appear to be orientated predominantly in a longitudinal
direction. The adventitia forms the outer layer of vein wall
and is often thicker than the media and consists of a loose
network of longitudinally orientated collagen bundles and
scattered fibroblasts through which the vasa vasorum of
the vein pass. The vasa vasorum of veins form an anasto-
motic plexus that provides resistance to ischaemic injury
when there is local interruption of these vessels.23,24 On
occasion, longitudinal or spirally arranged smooth muscle
cells may appear in areas of the adventitia adjacent to the
media. The endothelial cells appear as flat polygonal cells
with large centrally placed nuclei surrounded by a thin
cytoplasm with the usual organelles and large numbers of
plasmalemmal vesicles.25 The junctions between the cells
are mainly of a long occluding type and are consideredExtrinsic
Anastomotic problems
Inflow tract stenosis or occlusion
Outflow tract stenosis or occlusion
Thromboembolism
Graft sepsis
Mechanical compression of the graft (entrapment or kinking)
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Numerous microvilli can be demonstrated on the luminal
surface and lesser numbers of cytoplasmic processes
penetrate the subendothelial matrix.25,26 The smooth
muscle cells contain contractile fibres with dense bodies,
prominent subsurface vesicles and the usual organelles.
Veins are highly compliant over the range of venous
pressures and are relatively non-compliant at arterial
pressures.27 Veins have a high degree of lactic dehydro-
genase activity with lesser amounts of the other oxidative
enzymes.28 In addition, veins appear to have a different
metabolic profile and tissue content compared to arteries
which may in part account for the distinct patterns of lipid
accumulation found between veins and arteries.29e33
Although there is no difference in total protein content,
the amount of collagen appears to be greater in the
saphenous veins.33 The total content of glycosaminogly-
cans is also similar in the saphenous veins and internal
mammary arteries, although the major component
present in the internal mammary artery is heparan sulfate
while in the saphenous vein, derma- tan sulfate is the
dominant glycosaminoglycan.33 In association with these
structural and biochemical differences, there are differ-
ences in the vasomotor function of the saphenous veins
compared to the internal mammary arteries. Nitric oxide
and prostacyclin mediated relaxation responses of
saphenous veins are much less and the maximal contrac-
tile forces generated are much greater than the internal
mammary artery.34 In addition, local angiotensin con-
verting enzyme activity which converts angiotensin I to
angiotensin II and degrades bradykinin (a potent mediator
of nitric oxide release) is greater in the saphenous vein
compared to the internal mammary artery.34 Saphenous
veins demonstrate a spectrum of pre-existing pathological
conditions ranging from significantly thickened walls to
post phlebitic changes and varicosities at the time of
harvest. Between 2 and 5% of these veins are unusable and
up to 12% can be considered “diseased”.21 These
“diseased” veins have a patency rate one half that of
“non-diseased” controls. The etiology of the venous
diseases observed are multifactorial in origin and at the
present time without gross morphological evidence of
disease there is no clear prognostic indicator to discrimi-
nate those veins which should be rejected as grafts.21,22 It
is apparent that most saphenous veins excised have
a degree of intimal thickening and show altered in vitro
smooth muscle cell contractility which are not dependent
on donor age but can be positively correlated with donor
gender.17,20,35e37 Endothelial mediated relaxation appears
to be intact in the saphenous veins of patients undergoing
peripheral vascular surgery, although there are sugges-
tions that saphenous veins have a decreased ability to
release intraluminal nitric oxide and that smoking can
impair both nitric oxide and prostacyclin mediated
responses.19,34,38 A recent study of the morphological
features of veins which have been used for bypass has
shown intimal thickening and histological evidence of
early atheromatous changes in the intima39; additionally,
the compliance of the vein wall can be correlated with the
intimal thickness of the vessel.40 Primary cultures from
saphenous veins of patients undergoing venous bypass
reconstruction suggest that the smooth muscle cellphenotypes present demonstrate a spectrum of sensitivity
to growth inhibition by heparin.41Perioperative Period
Perioperative manipulations of veins prior to their insertion
have been shown to produce significant tissue damage.
Such implantation injury leads to endothelial dysfunction,
endothelial cell injury, endothelial denudation and smooth
muscle cell injury each of which are important factors in
the initiation of intimal hyperplasia. It is now recognised
that every effort should be made to reduce the degree of
implantation injury that a vein graft suffers.42e45 The basic
principles of optimal saphenous vein procurement have
been established by many studies and include as strict as
possible adherence to the “no touch” technique, where
there should be minimum manual and instrumental contact
with the vessel,46 the use of papaverine as a smooth muscle
cell relaxant,47e50 the use of an appropriate physiological
storage solution, the avoidance of cold procurement sol-
utions48,51e54 and the control of distension pressures to
w100 mmHg during vein perfusion.53,55e57 Storage of vein
grafts in non-physiological solutions (i.e. solutions which do
not have an electrolyte composition, pH, osmolarity and
temperature close to serum) leads to morphological
damage, loss of endothelium dependent vasomotor func-
tion (decreased prostacyclin and NO release) but appears to
leave smooth muscle cell contractility intact.58,59 During
this period of storage the vein grafts do not experience
significant hypoxia.60 Furthermore, injudicious distension
of veins (>100 mmHg) can produce both morphological and
functional injuries to the endothelial and smooth muscle
cells of the vein graft.53,56,57,61e65 The use of physiological
solutions containing papaverine with osmotic and pH char-
acteristics closer to serum or the use of whole blood to
store vein grafts has improved the quality of the harvested
vein graft, as assessed by functional, biochemical and
histological studies. There appears to be a direct relation-
ship between the morphological integrity of the vein graft
prior to grafting and its later histopathological appearance
and function.43,45 Poorly prepared vein grafts develop
significantly greater intimal hyperplasia and increased
smooth muscle cell contractility compared to carefully
prepared vein grafts.43,45
The in-situ technique is considered to prevent many of
the problems associated with implantation injury particu-
larly with regard to the body of the vein graft. In-situ vein
bypass grafts appear to have a greater degree of endo-
thelial preservation and superior endothelial cell function
compared to reversed vein grafts.66e73 Two recent articles
have suggested that the use of a valvutome in the in-situ
vein results in near total endothelial cell loss with an
associated endothelial and smooth muscle cell functional
deficit implying that this particular type of in-situ tech-
nique is not beneficial.74,75 It is to be expected that the
passage of a valvutome along the length of the vein which is
akin to the passage of an embolectomy catheter along an
artery would result in significant vessel wall injuries.
However, not all in-situ techniques require the full length
passage of a valvutome and studies using different tech-
niques would suggest that there is a significant morphologic
S22 M.G. Davies, P.-O. Hagenand functional benefit to the technique in the perioperative
period.66e73
Postoperative Period
The preservation of the endothelial cell layer during
harvest has changed the sequence of histological changes
observed after implantation. It is now apparent from
experimental and angioscopic studies that the endothe-
lium is preserved after implantation into the arterial
circulation. Current studies have demonstrated that
following exposure to the arterial environment, the cells
experience severe stretching and increased tangential
stress both of which contribute to endothelial cell
damage.24,76 Within 24 hours, the endothelial cells are
sandwiched between adherent luminal and infiltrating
subendothelial polymorphonucleocytes with platelet
deposition on the endothelial surface. In addition, there
is extensive subendothelial oedema which reflects
a combination of increased transmural flux and stretch
damage due to the vein graft’s distension by arterial
blood pressure. In experimental vein grafts smooth
muscle cell proliferation occurs within the first 72 hours
and continues for at least 7 days after insertion.77,78
Associated with the onset of proliferation, there are
changes in specific membrane G-protein subunit expres-
sion in the smooth muscle cells with the de novo
expression of ai and as subunits. Microscopic development
of intimal hyperplasia occurs later, from day 3 to 5 and
increases rapidly between 7 to 14 days. There is a loss of
contractile function with the onset of smooth muscle cell
proliferation in the vein grafts. This contractile function
returns with time after day 7. The pattern of smooth
muscle cell contractility is markedly different to the
control vein and is associated with additional changes in
the functional coupling of receptors to G-proteins in vein
grafts.79
Histological surveys of human saphenous vein grafts
have been derived from specimens obtained at autopsy or
at re-operation.24,80 Vein grafts obtained in the early
postoperative period (<24 hours) show focal loss of
endothelial cells particularly at the perianastomotic areas
and fibrin deposition on the intima. An increased perme-
ability of the endothelium has been observed with poly-
morphonucleocytes and platelet adherence to denuded
areas within one day postoperatively. In the following four
days, the deposition of intimal fibrin and the accumulation
of various blood cell elements on the endothelial surface
become more prominent. In addition, focal areas of
denuded endothelium due to cells sloughing are also
observed. By days 7 to 14, the endothelial cell layer in
these grafts can be redefined and at this time intimal
smooth muscle cells can be identified.24
Mechanisms of Vein Graft Failure
Intimal hyperplasia is the universal response of a vein
graft to insertion into the arterial circulation and is
considered to result from both the migration of smooth
muscle cells out of the media into the intima and prolif-
eration of these smooth muscle cells; later the smoothmuscle cells deposit an extracellular matrix. Macroscopi-
cally, intimal hyperplastic lesions appear pale, smooth,
firm and homogenous; they are uniformly located between
the endothelium and the medial smooth muscle cell layer
of a vein graft.81,82 Due to the lack of a well defined
internal elastic lamina in veins, the separation between
intimal and medial layers may be delineated by identifi-
cation of the demarcation between the criss-cross orien-
tation of the intimal hyperplastic smooth muscle cells and
circular smooth muscle cells of the media; the outer limit
of the media was defined by the interface between the
circular smooth muscle cells of the media and the
connective tissue of the adventitia. In general, intimal
hyperplasia is a self-limiting process which does not
produce luminal compromise and usually becomes quies-
cent within 2 years of graft insertion. However, in focal
areas, the intimal hyperplastic process can proceed to
significant stenosis.81e84 The first report of a vein graft
stenosis was in 196585 but it was not until 1971 that the
first report appeared citing intimal hyperplasia as the
cause of the late occlusion in an aorto-coronary vein
bypass graft86 but recent studies of peripheral vein grafts
have documented that the majority of stenotic lesions
which develop in a graft are composed of intimal hyper-
plastic tissue.83,84
The precise initiating stimuli for intimal hyperplasia
have not been fully defined but it appears to be the
response of the vascular smooth muscle cells to a combi-
nation of physical, cellular and humoral factors accompa-
nied by dysfunctional endothelial regulation.81,82,87,88
Fibroblast growth factors contribute significantly to the
medial proliferation of smooth muscle cells while the
presence of either endogenous or exogenous platelet
derived growth factors promote the migration of smooth
muscle cells from the media to the intima. Several other
mediators of both the tyrosine kinase (IGF-1, TGF-a,
a-thrombin and interleukin-1b) and G-protein (angiotensin
II, endothelin-1, serotonin) coupled membrane receptors
have been shown to participate in these initial events. The
mediators of the intimal proliferative response which
occurs after migration from the media are unclear as are
the factors which induce smooth muscle cell proliferation
to wane and the synthesis of extracellular matrix to begin;
however, there are suggestions that the activity of trans-
forming growth factor-b isoforms and endothelial cells are
important in this transition from an “activated” state to
a relative “quiescent” state.81,82,87
The majority of vein graft stenoses from human
peripheral bypass grafts can be classified as intimal
hyperplasia being highly cellular consisting predominantly
of smooth muscle cells with a variable amount of
connective tissue features similar to the intimal hyper-
plasia of animal models. During the initial perioperative
period after saphenous vein coronary grafting, early
stenosis and occlusions occurs in 5e8% of grafts due to
intimal hyperplasia.13,22,83,84,89 Primary cultures from
these stenotic lesions have suggested that the smooth
muscle cell phenotype present is more resistant to the
action of growth inhibitors such as heparin than other
areas of the graft.90 Saphenous vein grafts excised from
patients undergoing revision surgery continue to exhibit
dose-dependent contractile responses to the
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reduced compared to fresh saphenous veins.9193 Grafting
of saphenous veins appears to result in the loss of endo-
thelium-dependent relaxation responses to the receptor-
coupled agonists, but not to the receptor-independent
agonists.34,92e95 It is also suggested that endothelium
mediated relaxation is preserved in retrieved human
coronary vein bypass grafts but that there are significant
decreases in this response with increasing severity of the
intimal lesions.96 In addition to the decreased NO medi-
ated responses, there is a decrease in prostacyclin medi-
ated responses in retrieved vein grafts.34 Associated with
the decrease both NO and prostacyclin activity, the local
intrinsic fibrinolytic activity of vein grafts is reduced
compared to ungrafted veins.97,98 This combination of
decreased anti-aggregatory potential and fibrinolytic
activity results in an increased thrombogenic surface and
it is notable that two-thirds of vein grafts removed during
redo coronary artery bypass operation show evidence of
mural or occlusive thrombus.99
Changes in haemodynamic parameters have been
shown to affect the structure of both normal and
diseased vessels.100 Haemodynamic alterations are
implicated in the intimal response of vein grafts.40,101e112
Recent evidence suggests that deformation of smooth
muscle cells by arterial haemodynamics can lead to
activation of protein tyrosine kinases and thereby initiate
smooth muscle cell proliferation.113 Vein grafts with
lower flows are associated with greater intimal thick-
ening.105 Similarly low shear stress is also associated with
increased development of intimal hyperplasia in vein
grafts.106,108 Dobrin has shown in vein grafts that blood
flow (closely associated with shear stress) is best associ-
ated with the formation of intimal hyperplasia and that
deformation of the vessel wall in a circumferential
direction is best associated with medial thickening.109,111
Similarly, Morinaga reported that accelerated intimal
thickening develops in vein grafts under low flow condi-
tions (poor distal runoff) and is reversed when these
vessels are re-implanted into a system with normal
parameters of flow.110 Several studies have shown that
rigid external support of a vein graft reduces intimal
hyperplasia and can preserve endothelium dependent
responses in vein grafts.114e117 Other studies have sug-
gested a role for increased wall tension in the develop-
ment of intimal hyperplasia.107,112 In a recent study, it
has been shown that rabbit arterial vein grafts removed
from the arterial circulation after 2 weeks and returned
to the venous circulation for a further 2 weeks demon-
strate a significant regression of both intimal and medial
thickening in the re-implanted grafts with restoration of
endothelium dependent relaxation to all agonists.118 A
study by Fann using a similar procedure in a canine model
has shown that vein graft intimal hyperplasia is not
reduced when a graft implanted for 12 weeks is returned
to the venous circulation and harvested after an addi-
tional 12 weeks.119 However, the medial area regresses
significantly in this study suggesting that circumferential
deformation of the vessel wall is the dominant factor in
the stimulation of medial thickening, while alterations in
flow, are responsible for the decreases in intimal
hyperplasia.Diffuse dilatation or expansion of vein grafts is often
seen when they are used as aortorenal bypass
grafts.16,120,121 Approximately half of the vein grafts show
a nonprogressive, uniform enlargement of the graft which is
often as much as a 20% increase in the graft original
transverse diameter. The factors responsible for this early
dilatation may be a high flow rate and/or the expanding
influence of the arterial pressure in tissue relatively
unsupported by surrounding tissue. It has been suggested
that the degree of dilation is most probably controlled by
the concomitant development of intimal hyperplasia. Focal
dilation or aneurysm formation has been reported in vein
grafts irrespective of the site of insertion.16,122e126
Although these aneurysms may be associated with athero-
sclerotic changes, the tissue from many aneurysms often
does not differ histologically from the nonaneurysmal
portion of the patent vein grafts.
With few exceptions patients who undergo vein bypass
grafting have a significant degree of arteriopathy, and
concomitantly have one or more atherogenic risk factors
present. Hypertension in both human and experimental
models does not affect the development of intimal
hyperplasia in the short or long term.127e130 Furthermore,
it appears that hypertension is not associated with the
later development of vein graft atherosclerosis.127 In
contrast, both experimental and clinical studies have
shown an association of hyperlipidemia with the devel-
opment of intimal hyperplasia/atherosclerosis and with
higher vein graft failure rates.127,131,132 Clinically, dia-
betes does not appear to impact significantly on vein graft
patency but experimentally, it does increase short term
intimal hyperplasia development.127,133 In cases of
combined hypertension and hyperlipidemia, there appears
to be no additive effects on intimal hyperplasia develop-
ment in vein grafts compared to hyperlipidemia alone. In
contrast, however, the combined presence of diabetes and
hyperlipidemia has a significant additive effect on the
formation of intimal hyperplasia in experimental vein
grafts. Interestingly, the profile of vasomotor function of
vein grafts, in situations where more than one atherogenic
risk factor is present, is attenuated compared to the
comparative situation where only one disease state is
present and the observed profiles are very similar to those
observed in retrieved human vein grafts.79
The intimal hyperplastic lesions of vein grafts retrieved
one month after aorto-coronary bypass in humans have
been shown to consist of proliferating smooth muscle cells
with only scattered macrophages in the sub-
endothelium.134 Under hyperlipidemic conditions, venous
tissue has demonstrated an avidity for the uptake of serum
lipid surpassing that of arterial tissue in the same
species.29,135 Intimal hyperplastic lesions of experimental
hypercholesterolemic vein grafts are composed predomi-
nantly of lipid-laden smooth muscle cells with macro-
phages in various stages of foam cell formation
interspersed between these cells.131,132,136 Macrophages
are one of the principal cells involved in the development
of atherosclerosis through the oxidation of lipoproteins
and the formation of lipid peroxides.137e139 Oxygen free
radicals and lipid peroxides also interfere with the vaso-
motor function of both endothelial and smooth muscle
cells.140e143 Reduction of both cholesterol and low density
S24 M.G. Davies, P.-O. Hagenlipoproteins (LDL) is considered useful in slowing and
preventing atherogenesis.144 In experimental vein grafts,
reduction in serum cholesterol by 20% in hypercholester-
olemic rabbits with either lovostatin therapy or ileal
bypass surgery has resulted in a significant decrease in
total graft cholesterol content.145 In rabbits, a 74%
reduction in serum cholesterol concentrations over the
first 28 postoperative days is associated with a 26%
reduction in graft intimal thickness and the macroscopic
absence of atheromatous lesions in the graft wall
compared to untreated controls.146 A reduction of 26% in
serum cholesterol in patients at 4 years after aorto-
coronary bypass surgery using a combined cholestipol
and niacin therapy for two years reduced the occurrence
of stenotic and occlusive lesions in the vein bypass grafts
of 16% of the patients suggesting that reduction of serum
cholesterol may improve long term vein graft patency.147
With particular regard to peripheral vein graft stenoses,
no association has been found with patient age, sex,
presenting symptoms, hypertension, diabetes or the
condition of the outflow vessel. The incidence of stenosis
appears higher the longer (i.e. the more distal) the
insertion.148 Other studies have suggested that platelet
dysfunction, hyperfibrinogenemia and lipoprotein (a) may
be associated with an increased risk of stenosis develop-
ment.149,150 At present the association with smoking and
vein graft stenosis is equivocal.148,150
Vein grafts retrieved from patients with angiographic
evidence of occlusive disease demonstrate histologic
features of atherosclerosis.128,129,151e154 The earliest
these lesions have been seen is six months after implan-
tation. Thus, it appears that these late occlusions of vein
bypass grafts are due to the development of a rapidly
progressive and structurally distinct form of atheroscle-
rosis which has been termed “accelerated atheroscle-
rosis” in order to distinguish it from “spontaneousTable 2 Therapeutic control in experimental models.
Class Compound
Solutions Warm iso-osm
Mechanical PTFE support
Anti platelet Aspirin/dipyri
Antioxidant Desferrioxami
21-aminostero
Ca2þ channel Blocker Verapamil
Steroids Prednisolone
Immunosuppression Cyclosporine
ACE inhibitors Captopril
Cilazapril
Receptor Antagonists Ketanserin
Prazosin
Heparins Heparin
LMW heparin
Peptides Angiopeptin
Amino acids L-arginine
U-3 Polyunsaturated Fatty Acids Eicosapentaen
Yes: Intimal hyperplasia reduced by more than 25% of control.
No: No reduction in intimal hyperplasia or a reduction of less than 25atherosclerosis”.82 Accelerated atherosclerosis is
morphologically different to spontaneous atherosclerosis
in that its lesions appear to be diffuse, more concentric
and have a greater cellularity with varying degrees of lipid
accumulation and mononuclear cell infiltration. The
syndrome of accelerated atherosclerosis shares many of
the pathophysiological features of intimal hyperplasia,
however, the prime mediators of this type of atheroscle-
rosis are likely to be the macrophage. In addition the
endothelium overlying accelerated atherosclerotic lesions
expresses the class II antigens which are not observed in
spontaneous atherosclerosis.Therapeutic control of Intimal Hyperplasia
Intimal hyperplasia remains one of the major obstacles to
long term graft patency.155 Minimising the degree of
implantation injury appears to be a simple and effective
first step. Therapies to limit its development in vein
grafts continues to attract considerable attention;
however, no effective clinical regimen is presently
available to counter the intimal hyperplastic response
found in vein grafts. The use of aspirin is associated with
a decrease in early thrombotic events in vein grafts but
has not been documented to reduce the incidence of
restenosis or the development of atherosclerosis.156 The
various class of compounds which have shown promise in
experimental vein bypass models are shown in Table 2.
However, few have successfully been transferred to the
clinical arena. Furthermore, one must be cautious in
interpreting the results of clinical trials which have
attempted to pharmacologically reduce the development
of angioplasty induced hyperplastic restenosis, because
in many respects, vein graft intimal hyperplasia is
a distinct entity.Outcome
otic physiological solutions Yes43,45
Yes116,117
damole Yes157,158/No159
ne manganese Yes160
ids Yes161
Yes162
Yes163/No164
Yes158
Yes165
No158
Yes166
No167
Yes168,169/No170
No171
Yes172
Yes173
oic acid Yes174,175
% of control.
Vein Graft Pathophysiology S25Conclusion
The saphenous vein remains a mainstay of surgical therapy
for arterial occlusive disease. As a biologic conduit, it has
distinctive native properties and a degree of intrinsic
degeneration which can impact on subsequent perfor-
mance. The greater understanding of the sequence of
events in the preoperative, perioperative and post-
operative phases of vein grafting which have been gleaned
from experimental and clinical studies has allowed
a clearer definition of vein graft pathophysiology. Vein
grafts are living, constantly evolving conduits that adapt to
the arterial circulation with the development of intimal
hyperplasia but subsequently develop accelerated athero-
sclerosis each of which compromises patency. At present,
intimal hyperplasia is the principal impediment to more
durable grafts. The growing understanding of the pathobi-
ology of vein grafts will ultimately produce practical ther-
apeutic strategies to enhance graft function and control
intimal hyperplasia.Acknowledgements
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